A Phase II Trial of the Oral mTOR Inhibitor Everolimus in Relapsed Aggressive Lymphoma

Abstract

Purpose

The phosphatidylinositol 3-kinase signal transduction pathway members are often activated in tumor samples from patients with non-Hodgkin lymphoma (NHL). Everolimus is an oral agent that targets the raptor mammalian target of rapamycin (mTORC1). The goal of this trial was to learn the anti-tumor activity and toxicity of single-agent everolimus in patients with relapsed/refractory aggressive NHL.

Patients and Methods

Patients received everolimus 10 mg PO daily. Response was assessed after 2 and 6 cycles and then every 3 cycles until progression.

Results

Seventy-seven patients with a median age of 70 years were enrolled. Patients had received a median of 3 prior therapies and 32% had undergone prior transplant. The overall response rate (ORR) was 30% (95% CI: 20 - 41%) with 20 patients achieving a partial remission and 3 a complete remission unconfirmed. The ORR in diffuse large B-cell was 30% (14/47); 32% (6/19) in mantle cell; and 38% (3/8) in follicular grade III. The median median duration of response was 5.7 months. Grade 3 or 4 anemia, neutropenia, and thrombocytopenia occurred in 14%, 18%, and 38% of patients, respectively.

Conclusions

Everolimus has single-agent activity in relapsed/refractory aggressive NHL and provides proof-of-concept that targeting the mTOR pathway is clinically relevant.

Introduction

Patients with non-Hodgkin lymphoma (NHL) are highly treatable and often curable. However, up to 40% of patients with relapsed diffuse large B-cell NHL (DLBCL) die of their disease;(1) mantle cell lymphoma (MCL) is still not predictably curable,(2, 3) and there is substantial need to develop new treatments for transformed lymphoma (TL).(4) The PI3K/Akt/mTOR pathway is a key growth and survival pathway for cancer cells.(5-7) The mammalian target of rapamycin (mTOR) kinase, a key member of the pathway, is a 289-kDa serine-threonine kinase that exists in mutually exclusive complexes referred to as mTORC1 and mTORC2.(8) Each complex has several components one of which is mTOR, the catalytic subunit. The key mTORC1 components are Raptor (regulatory-associated protein of mTOR) and mLST8 (mammalian lethal with Sec13 protein 8). mTORC1 positively regulates cell growth and proliferation and has been characterized as rapamycin-senstive. The components unique to mTORC2 are Rictor (rapamycin-insensitive companion of mTOR) and mSIN1 (mammalian stress-activated protein kinase interacting protein). mTORC2 regulates Akt signaling and is characterized as the rapamycin-insensitve complex.

Rapamycin (sirolimus) (9) is the parent drug of the class of mTOR inhibitors that target mTORC1. The rapamycin analogs temsirolimus and everolimus are now approved by the United States FDA for renal cell carcinoma.(10, 11) These agents have demonstrated activity against lymphoma cells both in vitro (12) and in vivo. For example, single-agent temsirolimus has shown an overall response rate (ORR) of approximately 40% with a median duration of response (DR) and time to progression (TTP) of 6 months in two trials for relapsed MCL.(13, 14) A randomized phase III trial in relapsed MCL demonstrated a higher ORR with temsirolimus compared to standard chemotherapy, although the ORR in that trial was only 22%.(15) A phase I trial of everolimus in hematological malignancies demonstrated the safety of everolimus at a dose of 10 mg daily.(16) We have demonstrated safety and efficacy of single-agent everolimus at the 10 mg daily dose in patients with Waldenstrom's macroglobulinemia,(17) small lymphocytic lymphoma,(18) and relapsed Hodgkin lymphoma.(19)

Based on this preclinical work and the excellent toxicity profile of everolimus in previous studies, we performed a phase II clinical trial of single-agent everolimus in patients with relapsed aggressive NHL that had failed standard therapy.

Patients and Methods

Laboratory Experimental Methods

To demonstrate that the everolimus used in this clinical trial indeed did target the mTOR pathway in aggressive NHL we tested everolimus in vitro using the MCL cell lines Jeko1, Mino and Granta. These were obtained from the ATCC and grown in RPMI-1640 with 10% fetal bovine serum. The DLBCL cell lines, SUDHL6 and OCILy19 were a generous gift from Dr. L. Staudt (National Institutes of Health) and were grown in IMDM with 20% human serum. Everolimus was provided by Novartis Pharmaceuticals and was dissolved in 100% dimethyl sulfoxide to a stock concentration of 100mM and stored at −80°C. Annexin V-fluorescein isothiocyanate was obtained from BD Biosciences (San Diego, CA). For Western blot analysis: 5 × 10⁶ cells were treated with 1, 10 and 50nM everolimus for 24 hrs and immunoblotting was performed as previously described.(12) Antibodies for phosphorylated mTOR (Ser 2448), S6 ribosomal protein (Ser 235/236) and 4E-BP1 (Thr37/46) were purchased from Cell Signaling Technology (Danvers, MA). For the studies of cell proliferation the cells were cultured in 96-well round-bottom microtiter plates (Costar, Cambridge, MA) at a density of 5 × 10⁴ cells/well in the presence of various concentration of everolimus. Prior to harvesting, cells were pulsed with 1 μCi tritiated thymidine (³H-TdR, Amersham, Piscataway, NJ) for 18 hrs. ³H-TdR incorporation levels were determined using a Beckman scintillation counter (GMI, Ramsey, MN).

Cell survival was determined by annexin-V/Propidium iodide staining and flow cytometry. 0.5 × 10⁶ cells were cultured with various concentrations of everolimus for 48 hrs. Cells were then stained using 1 μg/ml annexin-V-FITC, washed once in annexin-V binding buffer and stained with 0.5 μg/ml PI and analyzed by flow cytometry (FACSCalibur, Becton Dickinson). Data analysis was performed with FLOW JO software (Becton Dickinson).

Clinical Trial Patients and Methods

A two-stage, phase II study was conducted to assess the proportion of patients with relapsed aggressive NHL who achieved a partial response (PR) or better after treatment with single-agent everolimus. The study was conducted through the Mayo Clinic Cancer Center and Dana Farber Cancer Center and was approved by the respective Institutional Review Boards. Patients were eligible if they had previously received therapy and had relapsed or were refractory to their last treatment. There was no limit on the number of prior therapies. Patients were required to have failed or be ineligible for stem cell transplant. The relapse was biopsy-proven within 6 months prior to enrollment. Additional eligibility criteria were age ≥18 years old; measurable disease by CT or MRI with at least one lesion >2 cm diameter; life expectancy of ≥ 3 months; ECOG performance status ≤2; absolute neutrophil count (ANC) ≥ 1,000 × 10(6)/L; platelet count ≥ 75,000 × 10(6)/L; hemoglobin ≥ 8 g/dL; serum creatinine ≤ 2× the upper limit of normal (ULN); serum total bilirubin ≤ 2 ULN (or direct bilirubin of <1.5 UNL); aspartate aminotransferase (AST) ≤ 3 × ULN (≤ 5 × ULN if liver involvement is present).

Patients received 10 mg of everolimus orally in the fasting state daily; 4 weeks was considered one cycle. A CBC was performed weekly during the first cycle and on day 1 of each subsequent cycle. At the time of retreatment the full dose of everolimus was prescribed if the platelet count was ≥40,000 × 10(6)/L, the ANC ≥1000 × 10(6)/L and there were no grade 3 or 4 non-hematological toxicities (NCI Common Toxicity Criteria version 3.0). Patients who did not meet the retreatment criteria had the dose held until recovery, followed by a stepwise dose modification to 5 mg daily, 5 mg every other day, and 5 mg every third day. Patients could receive white blood cell growth factors if neutropenia developed at physician discretion. Erythropoietin treatment for anemia was permitted per standard guidelines.

Patients were restaged for response after 2 and 6 cycles and every 3 cycles thereafter. Responses were categorized using the International Workshop Criteria.(20) Patients who progressed or had unacceptable toxicity at any time discontinued therapy. Patients with stable disease after 6 cycles continued treatment at physician discretion. Patients who had a CR on cycle 6 or later were to receive 2 additional cycles and then could either discontinue everolimus or continue at physician discretion. Patients with PR after 6 cycles continued until progression or toxicity.

Statistical Design

This phase II study used a modified two-stage Simon optimum design (21) to assess the efficacy and tolerability of everolimus in patients with aggressive lymphomas, where the modification is that accrual was not suspended for the stage I analysis. The ORR was estimated by the number of responses divided by the number of evaluable patients. A patient was considered evaluable for response if they received at least one dose of everolimus. Thirty-seven evaluable patients were required to test the null hypothesis that the true ORR for this regimen is at most 5% versus the alternative hypothesis that the true ORR is 20% or greater. The study had 90% power, with a 9% Type I error rate. A 95% binomial confidence interval for the true ORR was calculated. Due to promising early results, 40 additional patients with aggressive lymphoma were accrued to this study to provide access to everolimus and to better assess the response rate and toxicity profile of this regimen.

Duration of response (DR) was defined as the time from the date of documented response to the date of disease progression. Time to progression (TTP) was defined as the time from registration to the date of disease progression. Patients who had not yet progressed were censored at the date of their last evaluation. Time to discontinuation of active treatment was defined as the time from registration to the date the patient discontinued treatment. Patients who were still receiving treatment at the time of these analyses were censored at the date of their last evaluation. Progression-free survival (PFS) was defined as the time from registration to the date of disease progression or death from any cause. Overall survival (OS) was defined as the time from registration to death from any cause. The distributions of these time-to-event endpoints were estimated using the Kaplan-Meier method.(22) Toxicity was defined as an adverse event classified as being possibly, probably, or definitely related to study treatment.

Results

mTOR pathway is constitutively activated in aggressive lymphoma

Cyclin D1, a cell cycle protein downstream of mTOR is overexpressed in nearly all cases of MCL. To provide further rationale for using the mTOR inhibitor everolimus in MCL, we evaluated mTOR activity in 3 mantle cell lines Jeko, Mino and Granta by measuring the phosphorylation profile of mTOR itself and its immediately downstream substrates S6 ribosomal protein (S6RP) and 4E-BP1 by western blot analysis using antibodies directed against mTOR-specific phosphorylation sites for each protein. As shown in Figure 1A, we found that all the 3 mantle cell lines displayed a high expression of phosphorylated forms of S6RP and 4E-BP1 as well as mTOR on Ser2481. These data suggest that mTOR pathway is constitutively activated in mantle lymphoma and provides a rational target for therapeutic agents such as everolimus.

Figure 1.

A. Immunoblots of proteins from three mantle cell lymphoma (MCL) cell lines demonstrating constitutive activation of mTOR and the downstream proteins S6RP and 4EBP1. B. Everolimus is a potent inhibitor of p-S6RP in both MCL (Jeko) and diffuse large B-cell lymphoma (DHL6) cell lines. Everolimus has less effect on p-4EBP1 in Jeko and no effect on DHL6.

Everolimus attenuates phosphorylation of S6RP and 4E-BP1 in aggressive lymphoma

To confirm that everolimus is actually acting on its intended target in aggressive NHL, we examined the phosphorylation status of the mTOR itself and its target proteins 4E-BP1 and S6RP after treatement with everolimus. Jeko1 (MCL) and DHL6 (DLBCL) cells were cultured with 1, 10 and 50nM everolimus for 24 hrs and western blot analysis was performed using phospho specific antibodies to mTOR, S6 and 4E-BP1. Treatment with everolimus resulted in the abrogation of S6RP phosphorylation in a dose dependent manner in both the cell lines (Figure 1B). We also found that everolimus decreased the levels of p-4E-BP1 in a dose dependent manner in Jeko but not DHL6. We found similar results in previous experiments with rapamycin.(12) These results suggest that everolimus is indeed an mTORC inhibitor in aggressive NHL cells.

Blockade of mTOR signaling with everolimus inhibits the growth of aggressive lymphoma, with little effect on apoptosis

Inhibition of mTOR is known to induce cell cycle arrest in tumor cells. Jeko (MCL) and DHL6 (DLBCL) cells were treated with various doses of everolimus for 48hrs followed by an assay of proliferation. Everolimus inhibited the proliferation of both cell lines in a dose dependent manner with approximately 50% reduction in proliferation at 50 nm everolimus compared to controls (Fig 2A). Further experiments were performed to assess the effect of everolimus on lymphoma cell survival. The 3 MCL lines Jeko. Mino and Granta were treated with various doses of everolimus and viability was assessed by flow cytometry using Annexin/PI staining. Similar to our results with rapamycin(12) we found little effect on survival with was less than 10% inhibition of cell survival in all MCL cell lines without evidence of any dose-dependent effect (Fig 2B).

Figure 2.

A. Dose dependent inhibition of mantle cell proliferation (Jeko) and diffuse large B-cell lymphoma cell proliferation (DHL6) with the mTOR inhibitor everolimus. B. Treatment of three mantle cell lymphoma cell lines with everolimus has little effect on cell survival.

Patient Characteristics and Clinical Outcomes

A total of 77 patients were enrolled from September 2005 to September 2008. The patient characteristics and disease types are summarized in Table 1. The ORR was 30% (23/77; 95% CI: 20 - 41%) with 20 PR and 3 CRu (Table 2). Eighteen additional patients had stable disease and 29 patients progressed by the first assessment. Seven patients went off study before being evaluated for objective status. These results met the study design criteria for success at both the interim and final analysis time points. The ORR for DLBCL patients was 30% (14/47); 32% (6/19) for MCL; and 38% (3/8) for FLIII. None of the 3 patients with the other disease types (1 case of CLL that transformed to DLBCL, 1 patient with precursor T-lymphoblastic lymphoma, and 1 unspecified high-grade B-cell NHL) responded to everolimus. Tumor responses occurred relatively early, with a median time to response for responders of 2.0 months (range, 1.5 - 8.7 months). Sixteen responses occurred after 2 cycles, 1 response after 4 cycles, 5 responses after 6 cycles and 1 response after 9 cycles. The ORR in patients with a history of a SCT was 32% (8/25).

Table 1.

Patient Characteristics (n=77)

Characteristic	Number (%)
Age, years
Median (Range)	70 (36, 92)
Sex, male	46 (60)
Performance Status
0	22 (29)
1	44 (57)
2	11 (14)
Lymphoma Stage at Study Entry
1,2	10 (13)
3,4	67 (87)
Disease type
Diffuse large B-cell lymphoma	47 (61)
Mantle cell lymphoma	19 (25)
Follicular grade III	8 (10)
Transformed lymphoma	1 (1)
Precursor T lymphoblastic leukemia/lymphoma	1 (1)
Unspecified high grade B-cell lymphoma	1 (1)
Prior stem cell transplant	25 (32)
Presence of B-Symptoms	7 (9)
Number of Prior Therapy Treatments
Median (range)	3 (1, 15)
Type of Prior Therapy
Rituximab	74 (96)
Anthracycline	70 (91)

Table 2.

Response to everolimus by disease type.

Disease Type	n	ORR (95% CI)	CR	PR
Total	77	30% (20-41)	3	20
DLBCL	47	30% (17-45)	0	14
MCL	19	32% (13-57)	2	4
FL-III	8	38% (9-76)	1	2
Other	3	0	0	0

Abbreviations: ORR, overall response rate; CRu, complete remission unconfirmed; PR, partial remission; DLBCL, diffuse large B-cell lymphoma; MCL, mantle cell lymphoma; FL-III, follicular lymphoma grade III

The median DR for the responders (CRu/PR) was 5.7 months (95% CI: 3.6 – 12.3 months) and 5 responders remained progression free at 12 months. Overall, 69 patients have had disease progression and 62 patients have died (Fig 3). Fifty patients died from disease progression. Other causes of death included an adverse event in 4 patients (1 grade 5 cholecystitis unlikely related to treatment, 1 grade 5 intra-abdominal hemorrhage unrelated to treatment, 1 unspecified adverse event while receiving subsequent treatment, 1 sepsis unrelated to treatment), complications from bone marrow transplant (1 patient), graft verses host disease (1 patient), unproven disease progression (1 patient), death in hospice (1 patient), and unknown cause (4 patients). The median follow-up on living patients was 24 months (range, 10 - 48). The median TTP for all patients was 3.4 months (95% CI: 2.1 - 4.2); the median PFS was 3.0 months (95% CI: 2.1 - 3.9); and the median OS from study entry was 8.1 months (95% CI: 5.3 - 12.5).

Figure 3.

Time to progression (A) and overall survival (B) in 77 eligible patients with relapsed aggressive non-Hodgkin lymphoma treated with single-agent everolimus.

Safety and Tolerability

When considering adverse events of any cause, 43 patients (56%) experienced a grade 3 or higher hematologic adverse event (35% grade 3, 21% grade 4) and 41 patients (53%) experienced a grade 3 or higher non-hematologic adverse event (40% grade 3, 10% grade 4, 3% grade 5). Focusing only on adverse events at least possibly attributable to the study therapy (Table 3), 42 patients (55%) experienced a grade 3 or higher hematologic toxicity (35% grade 3, 19% grade 4). Grade 3 or 4 anemia, neutropenia, and thrombocytopenia occurred in 14%, 18%, and 38% of patients, respectively. Twenty-two patients (29%) experienced a grade 3 or higher non-hematologic toxicity (23% grade 3, 5% grade 4). The most frequent non-hematologic grade 3 or 4 toxicities were hyperglycemia (8%), fatigue (8%), and mucositis (3%)

Table 3.

Grade 3 and 4 toxicity (adverse events considered at least possibly related to everolimus) was observed in 68% (52/77) of patients. Thirty-four patients (44%) experienced at least one grade 3 toxicity and 18 (23%) experienced at least one grade 4 toxicity.

Toxicity	Grade		Total (%)
	3	4
	General
Fatigue	6	0	6 (8)
Mouth sores (mucositis)	2	0	2 (3)
Anorexia	1	0	1 (1)
Fever	1	0	1 (1)
Dehydration	1	0	1 (1)
Hypersensitivity	0	1	1 (1)
Edema	1	0	1 (1)
Hematologic
Anemia	10	1	11 (14)
Neutropenia	12	2	14 (18)
Thrombocytopenia	17	12	29 (38)
Metabolic
Hyperglycemia	6	0	6 (8)
Hypertriglyceridemia	1	1	2 (3)
Hypercholesterolemia	1	0	1 (1)
Hyponatremia	1	0	1 (1)
Hypokalemia	0	1	1 (1)
Tumor lysis syndrome	1	0	1 (1)
Renal failure	0	1	1 (1)
Hepatic
Aspartate aminotransferase	1	0	1 (1)
Infection
Respiratory	3	0	3 (4)
Skin	2	0	2 (3)
Urinary tract	1	0	1 (1)
Peri-anal	1	0	1 (1)
Pulmonary
Cough	1	0	1 (1)
Hypoxia	1	0	1 (1)
Dyspnea	1	0	1 (1)
Pneumonitis	1	0	1 (1)

Overall, 52 patients (68%) had at least one grade 3/4 toxicity at least possibly related to everolimus. Although most patients experienced toxicity, as described in Table 3, the incidence of most of these complications was low and they were manageable with dose interruptions and dose reductions. Thrombocytopenia was the cause of most dose reductions and was rapidly reversible with drug delays of typically one week. Three patients experienced grade 3 respiratory tract infection. Two additional patients had grade 3 pulmonary toxicity - one with cough and the other with dyspnea, hypoxia, and non-infectious pneumonitis.

The 77 patients received a median of 2.0 months of everolimus treatment (range, 1 day − 45.3+ months). Seventy-five patients have discontinued treatment with the most common reasons being disease progression (51 patients), adverse events (6 patients) and refusal (4 patients). The median time to discontinuation of treatment was 2.0 months (95% CI: 1.9 - 2.9 months). Five patients remained on drug for at least 12 months, 4 patients for ≥18 months, and 4 patients for ≥24 months.

Of the 77 patients who received at least one dose of everolimus, 7 did not complete cycle 1 and 7 additional patients went off at the end of cycle 1 leaving 63 pts who received >1 cycle. The median number of cycles at 10 mg daily was 2 (range, 1 – 12) with 87% (55/63) of patients receiving 10 mg daily at cycle 2. Of the 55 patients who received more than one cycle at the full dose level, 14 eventually required a dose reduction. Twenty-eight patients (36%) had dose reductions (19 patients) or treatment delays (17 patients). The most common causes of dose reductions were hematologic toxicity (thrombocytopenia or neutropenia), stomatitis, edema, and rash. Treatment delays were due to hematologic toxicity (thrombocytopenia, neutropenia), and infection.

Discussion

The PI3K pathway has been demonstrated to be constitutively activated in the majority of B-cell lymphomas as manifested by phosphorylation of S6K and 4E-BP1 (Fig 1).(12, 23, 24) Preclinical studies in cell lines and primary samples of aggressive NHL have demonstrated that rapamycin or its analogs has a significant anti-proliferative effect on these specimens but does not substantially inhibit tumor cell survival.(12) In this study we again demonstrated that everolimus, the mTOR inhibitor used in this clinical study, efficiently inhibits mTOR activity in aggressive lymphoma in-vitro as shown by decreased cell proliferation and inhibits levels of phosphorylation of the downstream targets S6RP and 4E-BP1. Other investigators have found similar results.(25) Everolimus can also sensitize MCL and DLBCL cell lines to a variety of cytotoxic agents, including doxorubicin and bortezomib.(26) This preclinical data provided the rationale to perform this large phase II study of single-agent everolimus.

Although the ORR result of 30% achieved with everolimus in this trial is modest, it is indeed significant for several reasons. Firstly, the relapsed aggressive patient population is particularly difficult to treat because they are typically older adults, heavily pretreated, and have tumors with high kinetic activity. In this study, the median age of the patients was 70 years and they had received a median of 3 prior therapies. The aggressive nature of the tumors in these patients is reflected in the substantial number of patients (18%) that went off-study after only 1 cycle. Thus, finding an ORR of 30% in this group is meaningful and provides the rationale for further studies of combinations. Secondly, the everolimus treatment in this study was single-agent providing clear proof-of-principle that the responses were due to everolimus and that this class of agents may play an important role in the treatment of NHL. The fact that the ORR was 30% with a median DR for responders of nearly 6 months fits with the preclinical data in NHL that suggested that inhibition of mTOR would produce responses. Thirdly, oral everolimus therapy was convenient and tolerable even for extended periods of time.

The everolimus results for relapsed DLBCL are similar to the ORR and DR found with single-agent lenalidomide.(27) The 32% ORR with everolimus in relapsed MCL is similar to the 40% we found in our previous trials of temsirolimus (13, 14) and higher than the 22% determined in the phase III trial.(15) In the first trial of lenalidomide for relapsed NHL, Wiernik et al(27) found tumor responses in 8 of 15 (53%) patients with MCL. These pilot results, if confirmed, suggest that both mTOR inhibitors and immunodulatory agents are active in MCL.

Everolimus and other mTOR inhibitors are generally well tolerated. The mTOR inhibitors as a class can produce apthous-type mouth ulcers, hyperlipidemia, dysgeusia that can produce mild weight loss, thrombocytopenia, and fatigue. Most all of these toxicities can be managed with dose interruption and dose reduction after the toxicity resolves. In the case of hyperlipidemia, the addition of a statin drug is often required to maintain mTOR inhibitor dose intensity especially if the patient has an anti-tumor response and will be on the drug for an extended period of time. We observed an 1% incidence of grade 3 dyspnea, a rate similar to that found in other studies with everolimus(28) or temsirolimus.(10, 15) The most recent report of everolimus used in relapsed neuroendocrine tumors had a 13% incidence of pulmonary toxicity.(29)

The promising activity of mTOR inhibition also has implications for adjuvant therapy in lymphoma. Armand et al.(30) found that patients with NHL or Hodgkin lymphoma who underwent graft verses host disease prophylaxis with sirolimus after reduced-intensity allogeneic SCT had an improved survival relative to patients who received prophylaxis with a calcineurin inhibitor plus methotrexate. Trials are underway in DLBCL to test whether adjuvant everolimus after standard rituximab-based chemoimmunotherapy has induced a CR can lower the risk of relapse.

The lack of response of many patients with relapsed aggressive NHL to everolimus in this trial indicates that a mechanism or mechanisms of resistance to mTORC1 inhibition exists or develops in these tumor cells. We have demonstrated that when NHL cells are treated with prototypical mTORC1 inhibitors such as rapamycin, that although mTORC1 is blocked, the cells activate Akt through mTORC2 signaling thus providing an escape mechanism.(12) This has led to a search for agents that will overcome this resistance or be synergistic with mTORC1 inhibitors. Sorafenib, a novel multi-kinase inhibitor that acts through inhibition of Raf-kinase and VEGF receptors, has synergistic activity in vitro with rapamycin.(31) This provided the rationale for a phase I/II ongoing trial of sorafenib and everolimus for relapsed B-cell malignancies. Rapamycin also has demonstrated synergy with the histone deacetylase inhibitor LBH589 and a phase I trials of LBH589 and everolimus are ongoing at multiple centers.(12) Understanding the mechanisms of resistance in lymphoma cells when exposed to these targeted agents will shed further light on the pathways important to the growth and maintenance of malignant B-cells and provide important leads into new mTOR based combinations for aggressive NHL.